- Simulations Plus, Inc. is a premier developer of modeling and simulation software for drug discovery and development.
- SLP counts with more than 250 clients, works with a significant number of professionals with PhDs, and more than 1300 publications have discussed SLP’s products.
- Management noted several key drivers, but the most relevant, in my view, is the increasing adoption of MIDD technology by both the pharma industry and regulators.
- If regulatory agencies continue to push for the use of modeling and simulation, SLP’s expertise will most likely be an asset for entities involved in R&D.
- If SLP continues to recruit scientific personnel, and signs new collaborations in support of improving the company’s software, SLP’s EBITDA margin would trend north.
For further details see:
Simulations Plus: Software For The Pharma Industry, Significant Upside Potential